Format

Send to

Choose Destination
J Natl Compr Canc Netw. 2019 Jun 1;17(6):644-648. doi: 10.6004/jnccn.2019.7304.

Prolonged Response to Anti-PD-1 Antibody Therapy in Chemotherapy-Refractory Cholangiocarcinoma With High Tumor Mutational Burden.

Author information

1
aUniversity of Alabama at Birmingham School of Medicine, Birmingham, Alabama.
2
bUniversity of New Mexico School of Medicine, Albuquerque, New Mexico; and.
3
cIndiana University School of Medicine, Indianapolis, Indiana.

Abstract

Management of advanced intrahepatic cholangiocarcinoma (iCCA) is challenging and overall survival is poor. Progress in the development of new therapeutic options for metastatic cholangiocarcinoma (CCA) has been slow; hence, to date, there are no approved second-line agents in this setting. Although the development of immune checkpoint inhibitors has significantly improved overall survival in a variety of malignancies, there has not been a clinically important impact in CCA. This report presents a 66-year-old patient with chemotherapy-refractory iCCA who experienced a prolonged response to immunotherapy. Tumor genome profiling revealed a high tumor mutation burden of 17 mutations per megabase in the absence of microsatellite instability. He was started on immunotherapy with nivolumab and has experienced an ongoing response for 16 months without clinical symptoms and only minimal radiologic disease.

PMID:
31200359
DOI:
10.6004/jnccn.2019.7304

Supplemental Content

Full text links

Icon for Sheridan PubFactory
Loading ...
Support Center